AIRE:NASDAQ, reAlpha Tech Corp.

AIRE stock overview

reAlpha Tech Corp. (AIRE:NASDAQ) closed at $0.352 on November 16, 2026, down 1.57% on the day. The stock trades 97.7% below its 52-week high of $15.03 and 9.5% above its 52-week low of $0.321. Over the past year, it lost 96.9%. reAlpha Tech Corp. is part of the Health Care sector.

Key figures

Price
$0.352
Day change
-1.57%
Volume
100,021
Average volume
153,437
Market cap
2M+
52-week range
$0.321 – $15.03
50-day average
$1.04
200-day average
$3.39

Price action over the past year

In 252 trading sessions since November 14, 2025, AIRE closed higher on 102 days (40%). Its best day was October 23, 2026 (+23.88%) and its worst was November 3, 2026 (-41.62%). The stock moved 10% or more in a single session 29 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

AIRE news

About reAlpha Tech Corp.

Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Similar stocks

Find more stocks like AIRE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.